Thomas Seidl, PhD

Thomas Seidl, PhD : Chief Science Officer, Member of the Board, President and Treasurer

Thomas assumed the role of CEO of the Company in November 2020. In preparation for commercialization, as of December 1st 2025, he has shifted his focus back to the technical aspects of the development program. He brings extensive experience in management, research, development, and clinical validation for breakthrough diabetes technologies. Currently, Thomas leads the development of the hollow glucose sensor as Chief Science Officer. As CSO, Thomas has led the optimization of the chemistry and coating process, the hollow sensor design and the fabrication process development. Prior to joining the Company, Thomas was Manager of Polymer Development at Bayer HealthCare, Diabetes Care. Thomas holds a BS (2000) in Chemistry and an MS in Cell and Molecular Biology (2002) from the University of Hawaii at Manoa. He earned his doctorate in Synthetic Organic Chemistry from Portland State University in 2017.